EOLS(EOLS)
EOLS
ANALYST COVERAGE13 analysts
BUY
▲ +133.3%upside to target
L $13.00
Med $15.00consensus
H $17.00PRICE
Prev Close
6.57
Open
6.49
Day Range6.33 – 6.67
6.33
6.67
52W Range3.86 – 10.62
3.86
10.62
38% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-9.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.18
Market-like
TECHNICAL
RSI (14)
74
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 119 days
Sep 15
Key MetricsTTM
Market Cap$423.45M
Revenue TTM$301.79M
Net Income TTM-$43.42M
Free Cash Flow-$41.33M
Gross Margin65.5%
Operating Margin-9.6%
Net Margin-14.4%
Return on Equity174.9%
Return on Assets-19.7%
Debt / Equity-5.73
Current Ratio2.04
EPS TTM$-0.67
EOLS News
About
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
David Moatazedi
Country
United States
Website
Kurt KnabSenior Vice President of Sales
Rui Avelar C.CFP Dip.SportMedChief Medical Officer and Head of Research & Development
David MoatazediPresident, Chief Executive Officer & Director
Jeffrey J. PlumerCorporate Secretary
Nareg SagherianHead of Global Investor Relations & Corporate Communications
Jessica NovakSenior Vice President of Human Resources
Tatjana MitchellChief Financial Officer
Tomoko Yamagishi-DresslerChief Marketing Officer